Active substance | Tolvaptan |
Holder | Otsuka Pharmaceutical Development and Commercialization, Inc |
Status | Running |
Indication | Treatment of Children and Adolescent Patients until they reach 18 years of age with Autosomal Dominant Polycystic Kidney Disease Following Successful Participation and Completion in the 156-12-298 Clinical Trial |
Public documents | Approbation |
Information for the patient | |
Informed consent | |
Last update | 10/08/2022 |